Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - pyridostigmine bromide, quantity: 60 mg - tablet, sugar coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; acacia; magnesium stearate; maize starch; povidone; liquid paraffin; purified talc; rice starch; hard paraffin; iron oxide red; sucrose; pregelatinised potato starch - indications as at 3 august 1992: mestinon is useful in the treatment of myasthenia gravis.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - fluorouracil, quantity: 50 mg/g - cream - excipient ingredients: methyl hydroxybenzoate; propyl hydroxybenzoate; polysorbate 60; white soft paraffin; purified water; propylene glycol; stearyl alcohol - indications as at 30 july 1990: solar and senile keratoses, bowen's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - tetrabenazine, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; maize starch; lactose monohydrate; magnesium stearate - may be useful for the control of chorea, hemiballismus, tardive and buccolingual dyskinesias and certain dystonic syndromes.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - prednisone, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; propyl hydroxybenzoate; maize starch; wheat starch - indications as at 26 march 1997 : wherever corticosteroid therapy is indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - prednisolone, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; wheat starch; maize starch; propyl hydroxybenzoate; lactose monohydrate; gelatin - indications as at 26 march 1997 : wherever corticosteroid therapy is indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - prednisolone, quantity: 25 mg - tablet, uncoated - excipient ingredients: wheat starch; magnesium stearate; gelatin; lactose monohydrate; maize starch; propyl hydroxybenzoate - indications as at 26 march 1997 : wherever corticosteroid therapy is indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metoclopramide hydrochloride monohydrate, quantity: 10.537 mg (equivalent: metoclopramide hydrochloride, qty 10 mg) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch; magnesium stearate; maize starch - indications as at 10 august 1994: adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. intramuscular administration of maxolon facilitates the absorption of a range of drugs including the absorption of aspirin in people with migraine. maxolon has been found useful in the management of gastric retention after gastric surgery. maxolon may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, maxolon should be discontinued. young adults and children: the use of maxolon in patients under 20 years should be restricted to the following s

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 35 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; gelatin - tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. acute and traumatic conditions of the limbs and trunk; sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

aquarium pharmaceuticals - malachite green (zinc free oxalate) | acriflavine - antibiotic & related - fish aquarium freshwater | cold water | tropical - not applicable (vet)

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - bisacodyl 5mg - enteric coated tablet - 5 mg - active: bisacodyl 5mg excipient: calcium carbonate colloidal silicon dioxide gelatin lactose monohydrate macrogol 6000 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone   purified talc   quinoline yellow silicon sodium starch glycolate starch sucrose